-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Initiates Coverage On Aktis Oncology with Overweight Rating, Announces Price Target of $30

Benzinga·02/03/2026 12:27:19
Listen to the news
JP Morgan analyst Jessica Fye initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Overweight rating and announces Price Target of $30.